Eli Lilly and Company's experimental obesity drug retatrutide delivered significant weight loss in a major late-stage trial, outperforming many existing GLP-1 therapies. Experts say the "triple G" medication could become a major breakthrough in obesity treatment, offering new hope for patients struggling with severe obesity, diabetes risk, and metabolic disease.